Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPAL-2: YM150 vs Warfarin in Non-Valvular Atrial Fibrillation
NCT00938730Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Jun 2009
- Primary completion
- Sep 2010
- Modality
- Small Molecules
- Countries
- 23
01
Overview
A Phase 2 trial of darexaban in Atrial fibrillation (AFib), sponsored by Astellas Pharma. Started Jun 2009; status: completed.
02
Drugs
darexaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT00938730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00938730.